August 4, 2025

Figure S5 from A RAS(ON) Multi-Selective Inhibitor Combination Therapy Triggers Long-term Tumor Control through Senescence-Associated Tumor-Immune Equilibrium in Pancreatic Ductal Adenocarcinoma

View Full Paper

Ask AI

Bookmark

The combination of RMC-7977 and palbociclib stimulates long-term tumor control in pancreatic ductal adenocarcinoma.
CD40 agonist enhances treatment efficacy, improving responses to the multi-selective inhibitor therapy.
This research utilizes a multimodal approach to target tumor progression and immune response mechanisms.
Findings suggest that managing immune equilibrium through therapy may advance treatment strategies for pancreatic cancer.

No abstract yet

We only have this paper's title and publication details.

Combination therapy shows prolonged tumor control in pancreatic ductal adenocarcinoma, indicating potential for improved immune responses.

CD40 agonist prolongs responses to RMC-7977 + palbociclib

No takes yet. Share an insight, caveat, or question.

Broderick et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Combination therapy shows prolonged tumor control in pancreatic ductal adenocarcinoma, indicating potential for improved immune responses.

CD40 agonist prolongs responses to RMC-7977 + palbociclib